SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Polyrizon Completes Enrollment of 120 Patients in U.S. NASARIX Study

Polyrizon says enrollment is complete for all 120 patients in its U.S. clinical study of the NASARIX allergy blocker.

PLRZ

Related stories